Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
HORIZANT 300 mg
DRUG
2 trials
Sponsors
XenoPort, Inc.
Conditions
RLS
Phase 1
A PK and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLS
Withdrawn
NCT02633657
XenoPort, Inc.
RLS
Start: 2016-01-31
End: 2017-07-19
Updated: 2021-04-12
Phase 4
An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS
NCT02560766
XenoPort, Inc.
RLS
Start: 2016-02-29
End: 2023-10-31
Target: 132
Updated: 2021-06-09